ATA-200 is a one-time gene therapy for the treatment of γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5), a serious and debilitating condition that affects children and ...

(ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program. The agreement enables ASTE, a pioneering healthcare distributor with over four ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

In particular, the company's main value drivers address myotonic dystrophy type 1 [DM1], Duchenne muscular dystrophy [DMD], ...

CK-089 is a fast skeletal muscle troponin activator (FSTA) with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired muscle function. "We are ...

Additional diseases that may be included in coverage are kidney failure, aplastic anaemia, muscular dystrophy, motor neuron ...

Windsor Paralympic champion, Danielle Campo, has been crowned the number one Inspirational Speaker of the Year for 2024 at ...

This drug, designed to address muscular dystrophy and other muscle function impairments, has shown improved muscle force and function in preclinical models, which builds confidence in its potential ...

Bernie’s Book Bank, a Lake Bluff, Illinois-based nonprofit, has named Jenna Renno as the first executive director of Bernie’s ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Find insight on Praram 9 Hospital, Sarepta Therapeutics and more in the latest Market Talks covering the Health Care sector.

Among its features, the lounge will include accessible seating with integrated space for wheelchairs, an accredited Changing Places toilet facility, a staffed welcome desk, and British Sign Language ...